Ghulam Murtaza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ghulam Murtaza has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Saiqa Nazeer
Department of Zoology, University of Gujrat, Gujrat, Pakistan
2 shared publications- Aniza Iftikhar
University of Gujrat, Pakistan
1 shared publication - Arooj Fatima
Department of Zoology, University of Gujrat, Gujrat, Pakistan
1 shared publication - Bilal Mukhtar
Department of Zoology, University of Chakwal, Chakwal, Pakistan
1 shared publication - Hajra Iqbal
Department of Botany, University of Gujrat, Gujrat, Pakistan
1 shared publication - Iram Asad
Department of Zoology, University of Gujrat, Gujrat, Pakistan
1 shared publication
Latest Publications
- Open Access
- 31 July 2026
- Published by Springer Nature in The Journal of Basic and Applied Zoology
- Vol. 87 (1) , 88
Prophylactic effects of Acacia nilotica gums on some biochemical and hematological parameters in asthmatic mice: qPCR analysis and histopathological examination
Background: Asthma is a chronic respiratory system disorder characterized by muscle tightness and inflammation around the tracheal tracks. Several anti-asthmatic drugs are available; however, they may have side effects. Acacia nilotica gums contain anti-inflammatory properties and can effectively treat diseases associated with inflammation. We explored therapeutic effect of Acacia nilotica gums against asthma using mouse ( Mus musculus ) as a model organism. Methods: The mice received ovalbumin on day one, and day fourteen. Whereas from day fifteen to twenty-six, herbal extracts were administered to all groups except asthmatic and normal control group. From days twenty-seven to twenty-nine, oral inhalation of ovalbumin was given to all treatment groups except the control group. Six treatment groups of mice (n = 3) were established, including a normal group and OVA, dexamethasone group (3 mg /mL), A. nilotica group (10 mg/mL), A. nilotica group (15 mg/mL) and A. nilotica group (20 mg/mL) and dose inhaled oral gauge. To determine biochemical and hematological parameters, complete blood count (CBC) and liver function tests (LFTs), leukocyte measurements, and protein levels of cytokines were carried out from blood and BALF serum, respectively. To find out the level of mRNA expression of interleukins (IL-5, IL-10, IL-4, IL-13, and IL-117A) and histology parameters, real-time polymerase chain reaction (PCR), and histopathological analysis were performed from lung of mice, respectively. Results: OVA-induced asthma led to a significant change in hematological indices, Liver function tests (LFTs) parameters, inflammatory cell infiltration, elevated pro-inflammatory cytokine level, change in cytokine gene expression. These changes were significantly ( p ≤ 0.05) reversed in a dose-dependent manner after treatment with the Acacia nilotica gums (10, 15 and 20 mg/mL). Acacia nilotica gums decreased the recruitment of inflammatory cells, decreased pro-inflammatory mediators, altered cytokine expression profile, and decreased airway remodeling and tissue damage. Histological investigations demonstrated reduction in airway constrictions (epithelium thickness, smooth muscle thickness, and bronchiole) in all treated groups except OVA. Conclusion: A. nilotica gums potentially alleviate asthma, improve hematological parameters, restore hepatic biochemical factors, and inhibit cytokines and enhance anti-cytokines.
- 31 July 2026
- Published by Springer Nature in The Journal of Basic and Applied Zoology
- Vol. 87 (1) , 88
Open AccessProphylactic effects of Acacia nilotica gums on some biochemical and hematological parameters in asthmatic mice: qPCR analysis and histopathological examination
Background: Asthma is a chronic respiratory system disorder characterized by muscle tightness and inflammation around the tracheal tracks. Several anti-asthmatic drugs are available; however, they may have side effects. Acacia nilotica gums contain anti-inflammatory properties and can effectively treat diseases associated with inflammation. We explored therapeutic effect of Acacia nilotica gums against asthma using mouse ( Mus musculus ) as a model organism. Methods: The mice received ovalbumin on day one, and day fourteen. Whereas from day fifteen to twenty-six, herbal extracts were administered to all groups except asthmatic and normal control group. From days twenty-seven to twenty-nine, oral inhalation of ovalbumin was given to all treatment groups except the control group. Six treatment groups of mice (n = 3) were established, including a normal group and OVA, dexamethasone group (3 mg /mL), A. nilotica group (10 mg/mL), A. nilotica group (15 mg/mL) and A. nilotica group (20 mg/mL) and dose inhaled oral gauge. To determine biochemical and hematological parameters, complete blood count (CBC) and liver function tests (LFTs), leukocyte measurements, and protein levels of cytokines were carried out from blood and BALF serum, respectively. To find out the level of mRNA expression of interleukins (IL-5, IL-10, IL-4, IL-13, and IL-117A) and histology parameters, real-time polymerase chain reaction (PCR), and histopathological analysis were performed from lung of mice, respectively. Results: OVA-induced asthma led to a significant change in hematological indices, Liver function tests (LFTs) parameters, inflammatory cell infiltration, elevated pro-inflammatory cytokine level, change in cytokine gene expression. These changes were significantly ( p ≤ 0.05) reversed in a dose-dependent manner after treatment with the Acacia nilotica gums (10, 15 and 20 mg/mL). Acacia nilotica gums decreased the recruitment of inflammatory cells, decreased pro-inflammatory mediators, altered cytokine expression profile, and decreased airway remodeling and tissue damage. Histological investigations demonstrated reduction in airway constrictions (epithelium thickness, smooth muscle thickness, and bronchiole) in all treated groups except OVA. Conclusion: A. nilotica gums potentially alleviate asthma, improve hematological parameters, restore hepatic biochemical factors, and inhibit cytokines and enhance anti-cytokines.
- Open Access
- 3 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0335877
Upregulation of interleukin-1β and interleukin-18 in traumatic brain injury patients and their potential as biomarkers
Background: Traumatic brain injury (TBI) is diagnosed using radiological imaging and biomarker analysis, each with certain limitations. Accurate and accessible detection of TBI is essential for its treatment. Since interleukin (IL)-1β and IL-18 are key neuroinflammatory cytokines, we aim to investigate the regulation of IL-1β and IL-18 in TBI patients and assess their potential as biomarkers of TBI. Methods: Forty TBI and 40 healthy subjects were recruited for this study. The Glasgow coma scale (GCS) was used to assess the clinical severity of TBI. Spearman’s rank-order correlation was employed to find the association between GCS scores and IL levels of TBI patients. An enzyme-linked immunosorbent assay (ELISA) with human IL-1β and IL-18 ELISA kits was conducted to measure the serum IL-1β and IL-18 levels. The area under the curve (AUC), sensitivity, and specificity were measured to assess the potential of IL-1β and IL-18 as biomarkers. Results: The patients had mild-to-moderate TBI (mTBI) with a mean GCS score of 11.05 ± 1.67. A negative correlation was found between GCS scores and IL levels, while IL-1 β and IL-18 were positively correlated with each other. IL-1β levels in the TBI and healthy subjects were 1882.19 ± 796.72 pg/mL and 1473.50 ± 333.045 pg/mL, respectively, with a significant difference (p = 0.001). Moreover, the IL-18 levels in TBI subjects (25.92 ± 14.81 ng/L) were also significantly higher (p < 0.001) compared to those of the control group subjects (19.14 ± 2.99 ng/L). The IL-1β exhibited an AUC of 0.72 with 72.5% sensitivity and 70% specificity, at a cut-off point of 1527.25 (pg/mL), while IL-18 had an AUC of 0.78 with 77.5% sensitivity and 72.7% specificity, at a cut-off point of 19.645 (ng/L). Conclusions: IL-1β and IL-18 levels were increased remarkably in mTBI patients and exhibited fair potential as biomarkers for the diagnosis and prognosis of TBI.
- 3 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0335877
Open AccessUpregulation of interleukin-1β and interleukin-18 in traumatic brain injury patients and their potential as biomarkers
Background: Traumatic brain injury (TBI) is diagnosed using radiological imaging and biomarker analysis, each with certain limitations. Accurate and accessible detection of TBI is essential for its treatment. Since interleukin (IL)-1β and IL-18 are key neuroinflammatory cytokines, we aim to investigate the regulation of IL-1β and IL-18 in TBI patients and assess their potential as biomarkers of TBI. Methods: Forty TBI and 40 healthy subjects were recruited for this study. The Glasgow coma scale (GCS) was used to assess the clinical severity of TBI. Spearman’s rank-order correlation was employed to find the association between GCS scores and IL levels of TBI patients. An enzyme-linked immunosorbent assay (ELISA) with human IL-1β and IL-18 ELISA kits was conducted to measure the serum IL-1β and IL-18 levels. The area under the curve (AUC), sensitivity, and specificity were measured to assess the potential of IL-1β and IL-18 as biomarkers. Results: The patients had mild-to-moderate TBI (mTBI) with a mean GCS score of 11.05 ± 1.67. A negative correlation was found between GCS scores and IL levels, while IL-1 β and IL-18 were positively correlated with each other. IL-1β levels in the TBI and healthy subjects were 1882.19 ± 796.72 pg/mL and 1473.50 ± 333.045 pg/mL, respectively, with a significant difference (p = 0.001). Moreover, the IL-18 levels in TBI subjects (25.92 ± 14.81 ng/L) were also significantly higher (p < 0.001) compared to those of the control group subjects (19.14 ± 2.99 ng/L). The IL-1β exhibited an AUC of 0.72 with 72.5% sensitivity and 70% specificity, at a cut-off point of 1527.25 (pg/mL), while IL-18 had an AUC of 0.78 with 77.5% sensitivity and 72.7% specificity, at a cut-off point of 19.645 (ng/L). Conclusions: IL-1β and IL-18 levels were increased remarkably in mTBI patients and exhibited fair potential as biomarkers for the diagnosis and prognosis of TBI.
- Open Access
Upregulation of interleukin-1β and interleukin-18 in traumatic brain injury patients and their potential as biomarkers
Background: Traumatic brain injury (TBI) is diagnosed using radiological imaging and biomarker analysis, each with certain limitations. Accurate and accessible detection of TBI is essential for its treatment. Since interleukin (IL)-1β and IL-18 are key neuroinflammatory cytokines, we aim to investigate the regulation of IL-1β and IL-18 in TBI patients and assess their potential as biomarkers of TBI. Methods: Forty TBI and 40 healthy subjects were recruited for this study. The Glasgow coma scale (GCS) was used to assess the clinical severity of TBI. Spearman’s rank-order correlation was employed to find the association between GCS scores and IL levels. An enzyme-linked immunosorbent assay (ELISA) with human IL-1β and IL-18 ELISA kits was conducted to measure the serum IL-1β and IL-18 levels. The area under the curve (AUC), sensitivity, and specificity were measured to assess the potential of IL-1β and IL-18 as biomarkers. Results: The patients had mild TBI (mTBI) with a mean GCS score of 11.05 ± 1.67. A negative correlation was found between GCS scores and IL levels. IL-1β levels in the TBI and healthy subjects were 1882.19 ± 796.72 pg/mL and 1473.50 ± 333.045 pg/mL, respectively, with a significant difference (p = 0.001). Moreover, the IL-18 levels in TBI subjects (25.92 ± 14.81 ng/L) were also significantly higher (p = 0.000) compared to those of the control group subjects (19.14 ± 2.99 ng/L). The IL-1β exhibited an AUC of 0.72 with 72.5% sensitivity and 70% specificity, at a cut-off point of 1527.25 (pg/mL), while IL-18 had an AUC of 0.78 with 77.5% sensitivity and 72.7% specificity, at a cut-off point of 19.645 (ng/L). Conclusions: IL-1β and IL-18 levels were increased remarkably in mTBI patients and exhibited fair potential as biomarkers for the diagnosis and prognosis of TBI.
Open AccessUpregulation of interleukin-1β and interleukin-18 in traumatic brain injury patients and their potential as biomarkers
Background: Traumatic brain injury (TBI) is diagnosed using radiological imaging and biomarker analysis, each with certain limitations. Accurate and accessible detection of TBI is essential for its treatment. Since interleukin (IL)-1β and IL-18 are key neuroinflammatory cytokines, we aim to investigate the regulation of IL-1β and IL-18 in TBI patients and assess their potential as biomarkers of TBI. Methods: Forty TBI and 40 healthy subjects were recruited for this study. The Glasgow coma scale (GCS) was used to assess the clinical severity of TBI. Spearman’s rank-order correlation was employed to find the association between GCS scores and IL levels. An enzyme-linked immunosorbent assay (ELISA) with human IL-1β and IL-18 ELISA kits was conducted to measure the serum IL-1β and IL-18 levels. The area under the curve (AUC), sensitivity, and specificity were measured to assess the potential of IL-1β and IL-18 as biomarkers. Results: The patients had mild TBI (mTBI) with a mean GCS score of 11.05 ± 1.67. A negative correlation was found between GCS scores and IL levels. IL-1β levels in the TBI and healthy subjects were 1882.19 ± 796.72 pg/mL and 1473.50 ± 333.045 pg/mL, respectively, with a significant difference (p = 0.001). Moreover, the IL-18 levels in TBI subjects (25.92 ± 14.81 ng/L) were also significantly higher (p = 0.000) compared to those of the control group subjects (19.14 ± 2.99 ng/L). The IL-1β exhibited an AUC of 0.72 with 72.5% sensitivity and 70% specificity, at a cut-off point of 1527.25 (pg/mL), while IL-18 had an AUC of 0.78 with 77.5% sensitivity and 72.7% specificity, at a cut-off point of 19.645 (ng/L). Conclusions: IL-1β and IL-18 levels were increased remarkably in mTBI patients and exhibited fair potential as biomarkers for the diagnosis and prognosis of TBI.